Category: Markets
Published: 2026-07-07T13:42:07.000Z
Enlivex Ltd (ENLV) announced a 1-for-15 reverse stock split effective July 9, 2026, a strategic move to increase its share price and comply with Nasdaq listing requirements. The biotechnology company, focused on developing Allocetra for osteoarthritis, has a P/E ratio of 0.1x, possibly indicating undervaluation, but its GF Score™ of 31/100 points to overall challenges, particularly in profitability despite strong financial health. No insider trading activity has been reported in the last 12 months.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.